Home Health News FDA Restricts Use of Immunotherapies in Gastric, Esophageal Cancers By News Health 2 months Ago Share on FacebookShare on Twitter (MedPage Today) — The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the respective drugmakers. The agency had… Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/116000 Author : Publish date : 2025-06-10 19:00:00 Copyright for syndicated content belongs to the linked Source. Categories: Health News Related Content Major Medical Groups Pushed Out of Role Supporting CDC's Vaccine Advisors By News Health August 1, 2025 'It's Gonna Be (Ly)me': Justin Timberlake Brings Attention, Awareness to Disease By News Health August 1, 2025 ACOG No Longer Accepting Federal Funding, Citing Policy Disputes By News Health August 1, 2025 States Sue Trump, Say Targeting of Hospitals Over Gender Care in Minors Is Unlawful By News Health August 1, 2025 Time Your Meals, Tune Your Metabolism By News Health August 1, 2025 Novel Eye Drops for Age-Related Blurry Vision Win FDA Approval By News Health August 1, 2025